Telix’ Double-Product Strategy On A Roll

Australia | 10:30 AM

Telix Pharmaceuticals' March quarter performance beat forecasts with company management lauding the two product PSMA imaging strategy.

  • Telix Pharmaceuticals’ March quarter impresses
  • Gozellix uptake drives volume and pricing
  • Illuccix continues to grow despite Gozellix competition
  • Guidance appears conservative amid strong demand

By Mark Woodruff

Telix Pharmaceuticals uses cancer-targeting molecules such as prostate-specific membrane antigen (PSMA) in its imaging and therapy programs

The full story is for FNArena subscribers only. To read the full story plus enjoy a free two-week trial to our service SIGN UP HERE

If you already had your free trial, why not join as a paying subscriber? CLICK HERE

MEMBER LOGIN

Lost your login details?

Remember me

Australian investors stay informed with FNArena – your trusted source for Australian financial news. We deliver expert analysis, daily updates on the ASX and commodity markets, and deep insights into companies on the ASX200 and ASX300, and beyond. Whether you're seeking a reliable financial newsletter or comprehensive finance news and detailed insights, FNArena offers unmatched coverage of the stock market news that matters. As a leading financial online newspaper, we help you stay ahead in the fast-moving world of Australian finance news.

Latest News

1
The Short Report – 10 Apr 2026

11:32 AM - Weekly Reports
2
Next Week At A Glance – 13-17 Apr 2026

11:23 AM - Weekly Reports
3
In Case You Missed It – BC Extra Upgrades & Downgrades – 10-04-26

11:00 AM - Weekly Reports
4
Weekly Top Ten News Stories – 10 April 2026

10:45 AM - Weekly Reports
5
Telix’ Double-Product Strategy On A Roll

10:30 AM - Australia

Most Popular

1
Weekly Top Ten News Stories – 13 March 2026

Mar 13 2026 - Weekly Reports
2
Material Matters: Rare Earths, Coal & Contractors

Mar 12 2026 - Commodities
3
Australian Broker Call *Extra* Edition – Mar 16, 2026

Mar 16 2026 - Daily Market Reports
4
ARB’s Growth Story Tested By Headwinds

Mar 16 2026 - Australia
5
WiseTech Juggling AI Risks And Growth Levers

Mar 11 2026 - Australia
6
FNArena Corporate Results Monitor – 25-03-2026

Mar 25 2026 - Australia